Gao Fen, Liu Lan, Li Fan
Respiratory Department, Affiliated Hospital of Qinghai University, Xining 810001, China.
Zhonghua Jie He He Hu Xi Za Zhi. 2010 Aug;33(8):578-81.
To investigate levels of platelet- activating factor (PAF) and nitric oxide synthase(NOS) in plateau asthma.
Peripheral blood platelet was counted and the serum level of PAF, TNOS, iNOS and cNOS were measured by ELISA in patients with asthma who lived at plateau and at plain respectively and healthy volunteers as the plan control group and in plateau control group. The data were expressed as x(-) ± s, and one way ANOVA was used for comparison of means; The correlation of 2 variables was estimated by Spearson rank correlation coefficience.
The PLT count was (166 ± 46) × 10(9)/L in the plateau asthma group and (140 ± 47) × 10(9)/L in the plateau control group, and both were significantly lower than those of the plain control group [(237 ± 98) × 10(9)/L] and the plan asthma group [(232 ± 71) × 10(9)/L, P < 0.01]. The levels of serum PAF in the asthma groups were higher than those of the control groups. The level of serum PAF in the plan asthma group [(877 ± 297) pg/L], was not only higher than that in the plan control group [(290 ± 132) pg/L], but also higher than that in the plateau asthma group [(429 ± 254) pg/L]; the difference being significant among groups (F = 66.08, P < 0.01). The PLT count showed a positive correlation with the level of PAF (r = 0.283, P < 0.01). The levels of TNOS, iNOS, and cNOS were not statistically different (P > 0.05) between the plain control group and the plateau control group. The levels of TNOS, iNOS and cNOS in plain asthmatic group [(36.2 ± 23.0), (20.3 ± 14.7) and (15.9 ± 8.4) U/ml respectively] were significantly higher than those of the plateau control [(11.9 ± 1.3), (9.4 ± 1.5) and (4.9 ± 0.5) U/ml] and the plateau asthmatic [(21.0 ± 2.3), (15.4 ± 2.5) and (5.3 ± 0.8) U/ml] groups(F = 17.197, 8.258, 34.250, respectively, P < 0.01). The increase of iNOS level was more significant.
Asthma in plateau area is associated with decrease of the levels of PLT, PAF and NOS.
探讨高原哮喘患者血小板活化因子（PAF）及一氧化氮合酶（NOS）水平。
分别对居住在高原和平原的哮喘患者及健康志愿者作为平原对照组和高原对照组进行外周血血小板计数，采用酶联免疫吸附测定法（ELISA）检测血清PAF、总一氧化氮合酶（TNOS）、诱导型一氧化氮合酶（iNOS）和内皮型一氧化氮合酶（cNOS）水平。数据以x(-) ± s表示，采用单因素方差分析比较均值；两变量的相关性采用Spearson等级相关系数进行评估。
高原哮喘组血小板计数为(166 ± 46) × 10(9)/L，高原对照组为(140 ± 47) × 10(9)/L，两者均显著低于平原对照组[(237 ± 98) × 10(9)/L]和平原哮喘组[(232 ± 71) × 10(9)/L，P < 0.01]。哮喘组血清PAF水平高于对照组。平原哮喘组血清PAF水平[(877 ± 297) pg/L]不仅高于平原对照组[(290 ± 132) pg/L]，也高于高原哮喘组[(429 ± 254) pg/L]；组间差异有统计学意义（F = 66.08，P < 0.01）。血小板计数与PAF水平呈正相关（r = 0.283，P < 0.01）。平原对照组和高原对照组TNOS、iNOS和cNOS水平差异无统计学意义（P > 0.05）。平原哮喘组TNOS、iNOS和cNOS水平[(分别为36.2 ± 23.0、20.3 ± 14.7和15.9 ± 8.4 U/ml)]显著高于高原对照组[(11.9 ± 1.3、9.4 ± 1.5和4.9 ± 0.5 U/ml)]和高原哮喘组[(21.0 ± 2.3、15.4 ± 2.5和5.3 ± 0.8 U/ml)]（F分别为17.197、8.258、34.250，P < 0.01）。iNOS水平升高更显著。
高原地区哮喘与血小板、PAF及NOS水平降低有关。
